STOKE THERAPEUTICS
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
STOKE THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2014-01-01
Address:
Bedford, Massachusetts, United States
Country:
United States
Website Url:
http://www.stoketherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
781-430-8200
Total Funding:
360.1 M USD
Technology used in webpage:
Amazon IPv6 Amazon Oregon Region Akamai Hosted Verizon Greenhouse
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Current Advisors List
Board_member
Board_member
Board_member
2015-09-01
Current Employees Featured
Edward Kaye CEO & Founder @ Stoke Therapeutics
CEO & Founder
2017-10-01
Isabel Aznarez VP, Biology and Co-Founder @ Stoke Therapeutics
VP, Biology and Co-Founder
2015-12-01
Huw Nash Founder, COO & CBO @ Stoke Therapeutics
Founder, COO & CBO
2017-10-01
Thomas Leggett Chief Financial Officer @ Stoke Therapeutics
Chief Financial Officer
2024-05-01
Adrian Krainer Co-founder & Director @ Stoke Therapeutics
Co-founder & Director
2014-01-01
Barry Ticho Chief Medical Officer @ Stoke Therapeutics
Chief Medical Officer
Stephen J. Tulipano CFO @ Stoke Therapeutics
CFO
2019-03-01
Sam Hall Director @ Stoke Therapeutics
Director
2015-07-01
Jason Hoitt Chief Commercial Officer @ Stoke Therapeutics
Chief Commercial Officer
2024-04-01
Founder
Stock Details
Investors List
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Stoke Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Stoke Therapeutics
RTW Investments
RTW Investments investment in Series B - Stoke Therapeutics
Sphera Funds Management
Sphera Funds Management investment in Series B - Stoke Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Stoke Therapeutics
Apple Tree Partners
Apple Tree Partners investment in Series B - Stoke Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Stoke Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Stoke Therapeutics
Redmile Group
Redmile Group investment in Series B - Stoke Therapeutics
Apple Tree Partners
Apple Tree Partners investment in Series A - Stoke Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-04-29 | Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer |
| 2024-04-17 | Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer |
Official Site Inspections
http://www.stoketherapeutics.com Semrush global rank: 2.58 M Semrush visits lastest month: 7.03 K
- Host name: 184.100.196.35.bc.googleusercontent.com
- IP address: 35.196.100.184
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Stoke Therapeutics"
Corporate Responsibility - Stoke Therapeutics
Stoke cares about building a positive culture both for our employees as well as in our local and patient communities. Our social responsibility efforts include volunteering time and resources …See details»
About Stoke - Stoke Therapeutics
Stoke Therapeutics - Crunchbase Company Profile
Contact Email info@stoketherapeutics.com Phone Number 781-430-8200 Stoke is developing antisense oligonucleotide medicines that target RNA splicing to …See details»
Stoke Therapeutics to Present at the Jefferies Global Healthcare ...
1 day ago BEDFORD, Mass.--(BUSINESS WIRE)--May 29, 2025-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by …See details»
Stoke Therapeutics (STOK) Company Profile & Description - Stock …
Jun 19, 2019 Company profile for Stoke Therapeutics, Inc. (STOK) stock, with a description, list of executives, contact details and other key facts.See details»
Press Releases - Stoke Therapeutics
Feb 26, 2025 Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates. May 13, 2025 – Regulatory alignment achieved for Phase 3 EMPEROR …See details»
Press Release Details - investor.stoketherapeutics.com
Jan 6, 2025 dkalmar@stoketherapeutics.com 781-303-8302 Doug Snow Director, Communications & Investor Relations IR@stoketherapeutics.com 508-642-6485 Source: …See details»
Careers & Culture - Stoke Therapeutics
What Makes Stoke Special. Stoke is a highly collaborative workplace, where mutual respect and admiration, paired with inclusivity, ensure that all team members have the opportunity to make significant contributions to the …See details»
Stoke Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
May 8, 2025 www.stoketherapeutics.com. Last update 08 May 2025. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. ... The …See details»
Biogen and Stoke Therapeutics Enter into Collaboration to …
Feb 18, 2025 dkalmar@stoketherapeutics.com 781-303-8302. Doug Snow Director, Communications & Investor Relations IR@stoketherapeutics.com 508-642-6485. Biogen …See details»
Stoke Therapeutics - VentureRadar
"Stoke Therapeutics (Nasdaq: STOK), is a clinical-stage biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating …See details»
Stoke Therapeutics - Overview, News & Similar companies
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a …See details»
Job Opportunities - Stoke Therapeutics
Those who observe suspicious recruiting activity involving Stoke are encouraged to report it to info@stoketherapeutics.com as well as to the Internet Crime Complaint center at …See details»
Pipeline - Stoke Therapeutics
Pipeline. Using the Company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively …See details»
Stoke Therapeutics to Present at the Jefferies Global Healthcare …
1 day ago dkalmar@stoketherapeutics.com 781-303-8302. Doug Snow Director, Communications & Investor Relations IR@stoketherapeutics.com 508-642-6485. 條款 及 私隱 …See details»
Press Release Details - investor.stoketherapeutics.com
May 13, 2025 dkalmar@stoketherapeutics.com 781-303-8302 Doug Snow Director, Communications & Investor Relations IR@stoketherapeutics.com 508-642-6485 Source: …See details»
Stoke Therapeutics - Work in biotech
Stoke Therapeutics is using new insights in RNA biology to address the underlying cause of severe diseases. Many diseases arise when one copy of a gene functions normally and the …See details»
Scientific Platform - Stoke Therapeutics
A Vision for Our Science. Our novel approach will allow us to pursue disease-modifying treatments for severe diseases. Using the TANGO approach and a deep understanding of …See details»
Press Release Details - investor.stoketherapeutics.com
Dec 31, 2024 – Phase 3 EMPEROR study of zorevunersen, a first-in-class potential disease-modifying medicine for Dravet syndrome, on track to initiate in 2Q 2025 – – As of December …See details»
Press Release Details - Stoke Therapeutics
Jan 10, 2022 – Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program – Acadia receives exclusive worldwide licenses for two …See details»